Crucially, despite its broad immunosuppressive properties, the PDE4 inhibitor roflumilast did not diminish the clinical activity of checkpoint inhibitors in a B-cell lymphoma mouse model. The gene discussed is PDE4A; the disease is B-cell non-Hodgkin lymphoma.